SAN DIEGO, CA--(Marketwire - February 13, 2013) - Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has promoted Leigh Hsu, Ph.D., to the new position of vice president of corporate development.
Dr. Hsu has more than 13 years of business-development experience in the biotech industry. Prior to joining Lpath in 2008 as its senior director of business development, he held positions of increasing responsibility at ACADIA Pharmaceuticals and Collateral Therapeutics (which became a subsidiary of Schering AG, now Bayer). Dr. Hsu played a key role in Lpath's $517 million licensing deal with Pfizer for iSONEP™, and has extensive deal experience with organizations like Wyeth and GE Healthcare, as well as with several academic and research organizations, including the University of California, the University of Texas, Southwestern Medical Center and the Veterans Medical Research Foundation.
"Leigh has played a key business-development role at Lpath," said the company's president and chief executive officer, Scott Pancoast. "He contributed strongly to our worldwide iSONEP partnership with Pfizer and has identified, and is now pursuing, several strategic licensing opportunities for Lpath. Leigh has become an instrumental member of the Lpath executive team, and we look forward to continued success on his part, not only with our business-development mission but with the corporate-strategy function as well."
In addition to Dr. Hsu's business experience, he has published numerous scientific papers in peer-reviewed journals, primarily in the area of the molecular basis of neurodegenerative diseases. He received his Ph.D. in Molecular Pathology from the University of California, San Diego, and his M.B.A. from the University of California, Irvine.
San Diego-based Lpath, Inc., a therapeutic antibody company, is the category leader in lipid-targeted therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company is developing three drug candidates: iSONEP™ is currently in a Phase 2 trial for wet AMD; ASONEP™ will soon begin a Phase 2 trial in Renal Cell Carcinoma patients; and Lpathomab is a preclinical drug candidate that holds promise in pain, neurotrauma, and other diseases.